logo

Moehs Group will participate in the CPhI India pharmaceutical fair, from November 28 to 31.

Moehs Group will participate in the CPhI India pharmaceutical fair, from November 28 to 31.

Leave a Comment / By

CPhI India 2019 will be held in Delhi and Moehs will be present at Stand 2.A15.

CPhI & P-MEC India is the ideal event for companies that want to know the latest trends and innovations that the market offers. In CPhI & P-MEC India, those that move the machinery, technology and ingredients industry market in India meet, which opens a competitive advantage to create business synergies among attendees.

 

When?

From November 28 to 31, 2019

 

Where?

India Expo Center, Greater Noida, Delhi

Stand 2.A15.

 

Do you want to contact?

Contact us for any information at: info@moehs.es

Leave a Comment

Your email address will not be published. Required fields are marked *

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.